THE US Food and Drug Administration (FDA) has approved oral weight-loss drug orforglipron (Foundayo, Eli Lilly) for adults with obesity, or overweight with weight-related medical problems.
"People living with obesity need treatment options that meet them where they are - and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment," said Dr Deborah Horn, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston.
"With Foundayo, we now have an oral option that delivered an average of 12.4% weight loss at the highest dose in clinical trials - addressing both the clinical realities of obesity and the practical challenges patients face every day," she added.
In addition to being tested for weight loss, studies have also found orforglipron delivered significant improvements in glycaemic control in patients with type 2 diabetes (PD 21 Oct 2025).
Sales of the drug commenced this week, and starting at around US$149 (A$210) per month for self-pay patients, the drug is significantly cheaper than Ozempic, which costs from US$350 (A$495).
Lilly has submitted the drug for weight management and/or T2D in over 40 countries - including Australia - with the FDA's approval expected to speed up the process.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Apr 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Apr 26
